Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
about
Risk factors for oligodendroglial tumors: a pooled international studyEnhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomicsOligodendroglioma: pathology, molecular mechanisms and markersComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Molecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationIntraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric StudyDifferential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.ImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomasReview: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesOligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall.Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes.Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesA phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumorsBiology, genetics and imaging of glial cell tumoursPrognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersHigh expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Molecular profile of oligodendrogliomas in young patientsAutomated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcomeGenetic markers in oligodendroglial tumours.Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.Anaplastic oligodendroglioma.Serum endocan levels before and after surgery on low-grade gliomas.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Recent developments in predictive biomarkers of pediatric gliomaPrognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups.Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population.
P2860
Q23910577-1523423F-21AD-413A-BC2F-20893AD0DA79Q24618080-014F2E90-4AD1-4AEC-94A2-A881B8E3EDD4Q27002448-48492B33-A718-48D4-9FDC-2D856A31E753Q27853175-BC32AB0A-957A-4746-B866-D275972FE43BQ28383205-795A47B3-E4D6-4608-A730-71728B28DC20Q30943327-175DF58D-8E41-4626-9846-69BEB9071BF4Q33532354-83D1C181-2360-4817-8204-8E88DAB34E7CQ33784207-5EEE3027-FF06-4FA1-BA50-173A96F0CF1CQ33925544-8CF42DC3-9551-49CB-BC88-4443665A9F78Q33942865-0C34E8FD-A4C8-4CF4-B8DD-FD515270BFB5Q34030544-82248B52-C4E4-48D1-878A-6558C4A41C20Q34132740-5DECC0ED-9AF8-4DE7-9205-B4008404CF25Q34132883-B83CBE1C-8A94-45E2-A170-0FAA59088434Q34203979-53AC8EE9-1D91-4191-9E4D-5118E0CB548CQ34388126-93AD6C50-3471-4D4D-871A-016B78D2C9D2Q34815207-2622854F-FAEB-481E-8AF7-07FE26329AC6Q35077834-DDAAF9FA-E716-44F3-9A52-CBCA33C2F3DBQ35204658-3339D3AF-EA87-4256-ADA7-F20815E7B1E6Q35225293-AE91450C-50B5-4977-8FF2-6850E8FDC8F5Q35681251-B422AD27-1F40-46F8-A4DF-F81B386490D2Q35845223-CE3FD74D-25EC-4CBA-B3C7-9CBC34D0B1AAQ36177607-5B235347-3158-477F-8D9C-CA729AFF11A1Q36904087-0DF12BEC-98C2-4108-9008-33243CA08E18Q36919406-94F94C57-6EF4-4416-AB86-161EA4A15C16Q37714906-38F46FAF-062C-464D-B8D0-01655FEFE56FQ37724813-7F3D82AB-A486-4369-8158-CA6C9A9BA6DBQ38203283-8FFF6E93-46A1-46A5-9956-3FFD2CD0DA6DQ38660101-94B10053-A20C-47F4-8333-FE292EE2C3B7Q47139133-13D83B75-A5A7-4F82-A7AB-43267C571507Q52598227-CD4462A9-1C07-448F-A8AD-DBCE59DBFDE8Q52629217-6CE21788-EC76-4A3E-A451-FDC69A5E4831Q55003744-8A31D99A-39E0-4845-AEB6-60DF23DE6621
P2860
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@ast
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@en
type
label
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@ast
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@en
prefLabel
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@ast
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@en
P2093
P1476
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
@en
P2093
Arie Perry
Kenneth Aldape
Peter C Burger
P304
P356
10.1043/1543-2165(2007)131[242:CAOQLA]2.0.CO;2
P577
2007-02-01T00:00:00Z